Medtronic Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Portfolio Pulse from Avi Kapoor
Medtronic plc (NYSE:MDT) is set to release its Q3 fiscal year 2024 earnings on Feb. 20, 2024, with analysts forecasting earnings of $1.26 per share and revenue of $7.95 billion. The company recently received CE Mark approval for its MiniMed 780G system and FDA approval for its Percept RC DBS system. Analysts from Truist Securities, Oppenheimer, UBS, Wells Fargo, and Stifel have provided various ratings and price targets for Medtronic, reflecting a mix of expectations.
February 20, 2024 | 7:23 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Medtronic is anticipated to report Q3 FY2024 earnings with a slight decrease in EPS from the previous year. Recent product approvals and mixed analyst ratings could influence stock performance.
The slight decrease in expected EPS year-over-year may concern investors, but recent product approvals could offset negative sentiment. Analyst ratings are mixed, indicating uncertainty about the stock's direction in the short term. The overall impact is neutral as positive product news and mixed analyst expectations balance out.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100